Business Context and Reporting Period
This Form 8-K is filed by AdventRX Pharmaceuticals, Inc. (not Savara Inc.) for the reporting period of April 5, 2004. The filing details a significant equity financing event and the issuance of warrants to investors and financial advisors.
Key Financial Metrics
The filing does not provide revenue, profit, or operating cash flow data as the company is in the development stage. Key capitalization and liquidity metrics are as follows:
- Gross Proceeds: $15,376,450 from the sale of 10,250,958 shares of Common Stock at $1.50 per share.
- Warrants Issued: 3,075,273 warrants at $2.00 exercise price and 2,050,185 warrants at $2.50 exercise price.
- Transaction Costs: $922,902.50 paid to Burnham Hill Partners; $25,920 paid to Ernest Pernet; $275,000 retainer paid to W.R. Hambrecht + Co., LLC.
- Liquidity (Pro Forma): Cash and cash equivalents increased from $4,226,397 (actual as of 12/31/03) to $18,379,025 (pro forma).
- Total Assets (Pro Forma): $18,435,984.
- Accumulated Deficit: $(28,481,146) as of December 31, 2003.
Material Changes
The primary material change is the substantial increase in cash reserves resulting from the April 8, 2004 closing of the stock sale. Additionally, the company completed the conversion of all outstanding Series A and Series B Preferred Stock into Common Stock in March 2004, eliminating preferred equity classes.
Guidance, Risks, and Contingencies
- Registration Obligation: The company must file a Form S-3 registration statement by June 30, 2004, to register the resale of shares and warrant-issued stock.
- Liquidated Damages: Failure to file the S-3 by June 30, 2004, or failure to have it declared effective by September 28, 2004, will result in liability for liquidated damages.
- Warrant Redemption: Warrants may be redeemed by the company at $0.01 per share if the stock price exceeds 200% of the exercise price for 20 consecutive trading days and shares are registrable or eligible under Rule 144.
- Future Commissions: Burnham Hill Partners is entitled to a 4% cash commission on future cash exercises of the warrants.
Investor Verification Checklist
- Verify the effective date of the Form S-3 registration statement to assess liquidated damages risk.
- Confirm the dilution impact of the 5,125,458 total warrants issued to investors and advisors.
- Review the company's burn rate to determine how long the new $15.4 million cash balance will sustain operations.
- Check for any subsequent filings regarding the conversion of preferred stock to ensure no residual preferred equity remains.